Skip to main content

CORRECTION article

Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1519505

Corrigendum: The Value of Second-line Anti-HER2 Therapy in Metastatic HER-2 Positive Patients: A Cost-effectiveness Analysis in China

Provisionally accepted
Lu Li Lu Li 1Shilei Yang Shilei Yang 1Fengqi Fang Fengqi Fang 2Li Tian Li Tian 1*Ying He Ying He 1*Jia Li Jia Li 2*Yanwei Chen Yanwei Chen 1*Deshi Dong Deshi Dong 1*
  • 1 Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China
  • 2 Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China

This article is a correction to:

  1. The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China

    1. Read original article

The final, formatted version of the article will be published soon.

    In the published article, there was an error. [There was a clerical error in writing]. A correction has been made to [Abstract], [Findings], [Paragraph One]. This sentence previously stated: “[The PC strategies are considered more cost-effective than T-DXd when the WTP threshold is set at $36,058.06 per QALY.]” The corrected sentence appears below: “[The PC strategies are considered more cost-effective than T-DM1 when the WTP threshold is set at $36,058.06 per QALY.]” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

    Keywords: HER-2-positive metastatic breast cancer, Network meta-analysis, cost-effectiveness analysis, Pyrotinib plus capecitabine, T-DM1

    Received: 30 Oct 2024; Accepted: 01 Nov 2024.

    Copyright: © 2024 Li, Yang, Fang, Tian, He, Li, Chen and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Li Tian, Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China
    Ying He, Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China
    Jia Li, Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China
    Yanwei Chen, Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China
    Deshi Dong, Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.